1. Home
  2. MLCO vs NKTR Comparison

MLCO vs NKTR Comparison

Compare MLCO & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Melco Resorts & Entertainment Limited

MLCO

Melco Resorts & Entertainment Limited

HOLD

Current Price

$5.32

Market Cap

2.2B

ML Signal

HOLD

Logo Nektar Therapeutics

NKTR

Nektar Therapeutics

HOLD

Current Price

$71.92

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLCO
NKTR
Founded
2003
1990
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.2B
IPO Year
2006
1996

Fundamental Metrics

Financial Performance
Metric
MLCO
NKTR
Price
$5.32
$71.92
Analyst Decision
Buy
Strong Buy
Analyst Count
5
7
Target Price
$10.10
$146.67
AVG Volume (30 Days)
1.5M
524.9K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$307,711,000.00
Revenue This Year
$5.42
N/A
Revenue Next Year
$4.37
N/A
P/E Ratio
$12.16
N/A
Revenue Growth
N/A
86.00
52 Week Low
$5.07
$27.87
52 Week High
$10.15
$109.00

Technical Indicators

Market Signals
Indicator
MLCO
NKTR
Relative Strength Index (RSI) 41.77 47.52
Support Level $5.13 $70.48
Resistance Level $5.73 $76.45
Average True Range (ATR) 0.17 2.81
MACD -0.03 -0.39
Stochastic Oscillator 33.83 23.74

Price Performance

Historical Comparison
MLCO
NKTR

About MLCO Melco Resorts & Entertainment Limited

Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 84% from Macao, with the rest from overseas as of 2025.

About NKTR Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

Share on Social Networks: